Tonix scraps Covid-19 li­cens­ing deal af­ter just three months — shares spike

Pen­ny stock biotech Tonix Phar­ma­ceu­ti­cals re­port­ed in an SEC fil­ing Mon­day that it was end­ing a li­cens­ing deal with New York in­fec­tious dis­ease and on­col­o­gy start­up Oy­a­Gen. Tonix was slat­ed to in-li­cense Oy­a­Gen’s SARS-CoV-2 in­hibitor can­di­date san­gi­vamycin in a deal an­nounced in April.

The move re­sult­ed in Tonix’s stock price $TNXP jump­ing 45%, end­ing the day at $1.73 a share.

Oy­a­Gen had giv­en Tonix the op­tion to ac­quire the rights for any­thing com­ing out of its plat­form “for the pre­ven­tion or treat­ment of Covid-19 de­vel­oped by Oy­a­Gen dur­ing the term of the Li­cense Agree­ment,” ac­cord­ing to the fil­ing. It al­so states:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER